Traws Pharma reports FY2024 net loss of $166.5M; CEO Werner Cautreels retiring, Iain D. Dukes Interim CEO

Traws Pharma, Inc.

2025-Q1 EPS reported $2.09 revenue$57,000

Net loss of $166.5M ($35.21/share) for FY2024, driven by $117.5M acquired IPR&D and $24.4M warrant expense.
Cash, cash equivalents and short-term investments $21.3M as of Dec 31, 2024; cash runway into Q1 2026.
CEO Werner Cautreels retiring as of March 31, 2025; Interim CEO Iain D. Dukes appointed, continuing as Chairman.
Lead candidate tivoxavir marboxil shows positive efficacy in three animal models for H5N1 bird flu; Phase 1 complete; FDA interaction sought under Animal Rule.
R&D expense $12.8M (up $1.4M); G&A expense $12.3M (up $3.2M) for FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.